November 01, 2023
Video
John Michael Kaczmar, MD, discusses future implications for the use of fianlimab in combination with cemiplimab for the treatment of patients with advanced melanoma.
October 04, 2023
Video
Alexander I. Spira, MD, PhD, FACP, discusses the evaluation of the LAG-3 inhibitor fianlimab plus cemiplimabin patients with advanced melanoma who were PD-L1 inhibitor–naïve, as seen in the findings from a phase 1 study.
September 06, 2023
Video
Meredith McKean, MD, MPH, discusses the rationale for investigating the LAG-3 inhibitor fianlimab in combination with cemiplimab-rwlc in patients with advanced melanoma, highlighting the combination's efficacy in both PD-1 inhibitor-exposed and –naïve populations, as well as the combinations its potential clinical significance within the advanced melanoma space.
June 26, 2023
Article
The combination of fianlimab and cemiplimab represents a wave of novel anti–LAG-3/PD-1 treatments being explored in patients with melanoma at high risk for relapse.
June 13, 2023
Video
Omid Hamid, MD, discusses the investigation of the LAG-3 inhibitor fianlimab in combination with cemiplimab in patients with advanced melanoma who were naïve to anti–PD-1 agents in the advanced setting.
June 06, 2023
Article
The LAG-3 inhibitor fianlimab plus cemiplimab produced high and consistent tumor responses and a comparable toxicity profile to that of anti–PD-L1 monotherapies in patients with advanced melanoma who were PD-L1 inhibitor–naïve in the advanced setting, according to data from a phase 1 study.